9 September 2021 - Deborah Wilkes
Enzymatica’s new chief executive has taken office ahead of schedule, Plexus Ventures has promoted Gabriele Tundo, and Lonza has a new chief financial officer.
Enzymatica gets new chief ahead of schedule
Enzymatica – the Swedish company behind the ColdZyme common cold spray – said Claus Egstrand had moved up to chief executive officer ahead of schedule.
The company announced in July 2021 that Egstrand had been promoted to chief executive officer and would take up his new position “at the latest on 1 January 2022” (click here to read the News story).
Enzymatica said “other engagements pointed at a possible start on 1 January 2022” but “these other engagements have now come to an end”.
Plexus Ventures promotes Tundo
Plexus Ventures – the corporate and business development consultancy focusing on healthcare – has promoted Gabriele Tundo from vice president to partner.
The US-based company said Tundo had contributed to projects involving mergers and acquisitions, asset divestment and licensing, as well as implementing successful business development campaigns in various countries and segments of the healthcare industry.
Tundo had recently led the development of Plexus’ capabilities in the field of digital therapeutics, added the company, resulting in the creation of a partnership with the Healthware Group.
Plexus has also promoted Daniel Sieiro from scientific associate to manager, innovation.
Lonza appoints finance chief
Switzerland’s Lonza has appointed Philippe Deecke as chief financial officer with effect from 1 December 2021.
He will take over from Rodolfo Savitzky who is leaving the chemicals and biotechnology company for a “new opportunity” on 31 December 2021.
Deecke will be a member of the Lonza Executive Committee.
He joins Lonza from Novartis where he most recently held the position of global chief financial officer for Novartis Oncology.
Before joining Novartis in 2005, Deecke spent more than six years at McKinsey.